메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT02…

BEIJING, Dec. 21, 2025 -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblastoma (rGBM). This milestone marks a significant breakthrough in addressing one of the most formidable challenges in oncology: developing effective allogeneic CAR-T therapies for solid tumors. "The FDA's clearance of the IND for MT027 represents a strong validation of our strategic commitment to tacklin
- 김갑성 기자
- 2025-12-21 20:20
Jacobio Pharma Enters Global Exclusive License Agreemen…

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China. Under the terms of the agreement, Jacobio will receive an upfront payment of US$100 million, and is eligible for additional development and commercial milestone payments of up to US$1.915 billion, as well as tiered royal
- 김갑성 기자
- 2025-12-21 20:15
Alphamab Oncology Announces Biparatopic HER2-targeting…

SUZHOU, China, Dec. 20, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube c
- 김갑성 기자
- 2025-12-20 12:54
Gene Solutions Concludes Successful ESMO Asia Congres…

SINGAPORE, Dec. 20, 2025 -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company's exhibition booth. 2025 has marked a year of substantial progress for Gene Solutions, with expanded presence and partnerships across India, Turkey, Taiwan
- 김갑성 기자
- 2025-12-20 11:14
Ceretone Showcases Core One Pro -- The Nearly Invisible OT…

[ 메디채널 김갑성 기자 ] Ceretone invites CES attendees to experience its latest penny-sized, feather-light hearing solution and complimentary hearing tests at Booth #54619 LAS VEGAS, Dec. 20, 2025 -- Ceretone, a consumer health technology company dedicated to making quality hearing solutions accessible and affordable, announces its participation at the Consumer Electronics Show (CES) 2026 in Las Vegas, Nevada, from January 6–9, 2026. At Booth #54619 in the Venetian Campus, Halls A-D, Ceretone will showcase its newest product, the Core One Pro, a next-generation OTC hearing aid designe
- 김갑성 기자
- 2025-12-20 02:00
Pictor's Test Poised to Transform Hepatitis B Immunity Testing…

CARLSBAD, Calif., Dec. 19, 2025 -- With the CDC's Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testing for hepatitis B, laboratories are facing new demands to assess immunity more effectively. Pictor, a leader in targeted proteomics, today highlighted its ViraScreen-Core™ multiplex antibody assay, an established test already in use by CLIA-certified laboratories, as a ready solution to support this evolving public health guidance. Built for both serum and saliva, the assay offers unmatched flexibility for labs adapting to these changes whi
- 김갑성 기자
- 2025-12-19 22:17
VARON Enhances Customer Access to Oxygen Concentrator…

NEW YORK, Dec. 19, 2025 -- As more individuals, families, and caregivers research oxygen therapy solutions online, knowing where to buy a reliable oxygen concentrator has become an important part of the decision-making process. With increasing demand for clear product information, authentic devices, and dependable after-sales support, VARON continues to strengthen customer access through its official online store. By purchasing directly from the VARON official website, customers can explore a complete range of oxygen concentrators for home and portable use, suppor
- 김갑성 기자
- 2025-12-19 19:52
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate…

SHANGHAI, Dec. 19, 2025 -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship and transparent disclosure. Climate Change Leadership Being recognized with an "A" rating by CDP for Climate Change affirms WuXi Biologics' leadership in environmental performance. The company's integrated climate change strategy – which has been validated by SBTi – is anchored in a clear goal of achieving net-zero emissions across its value chain
- 김갑성 기자
- 2025-12-19 17:30
Prepare for a Healthier Holiday Season with Wellness Tips fro…

MANILA, Philippines , Dec. 19, 2025 -- As the holiday season begins to unfold in the Philippines, families are starting to plan gatherings, reunions, and early celebrations. For households with elderly relatives or loved ones managing respiratory conditions such as COPD, asthma or other breathing difficulties, this period of increased activity can bring added considerations for health and comfort. VARON Philippines highlights the importance of respiratory wellness during the holidays, noting that home oxygen concentrators offer reliable support at home, while port
- 김갑성 기자
- 2025-12-19 13:48
SG-based Startup Galatek Raises $30M Series A to Accelerate…

SINGAPORE, Dec. 19, 2025 -- Galatek, a fast-growing Singapore-based automation and artificial intelligence (AI) startup, announced today that it has secured approximately US$30 million in Series A funding. The funding will accelerate the company's development of innovative products in life sciences and advanced semiconductor manufacturing, strengthen its global supply chain, and deepen local expertise in key markets across Europe, North America, and Southeast Asia. As AI continues to accelerate digital transformation across industries, Galatek addresses critical challenges in life scie
- 김갑성 기자
- 2025-12-19 10:47

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-21_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 21일 22시 10분